A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021

Importance: While much of the attention on the COVID-19 pandemic was directed at the daily counts of cases and those with serious disease overwhelming health services, increasingly, reports have appeared of people who experience debilitating symptoms after the initial infection. This is popularly known as long COVID. Objective: To estimate by country and territory of the number of patients affected by long COVID in 2020 and 2021, the severity of their symptoms and expected pattern of recovery Design: We jointly analyzed ten ongoing cohort studies in ten countries for the occurrence of three major symptom clusters of long COVID among representative COVID cases. The defining symptoms of the three clusters (fatigue, cognitive problems, and shortness of breath) are explicitly mentioned in the WHO clinical case definition. For incidence of long COVID, we adopted the minimum duration after infection of three months from the WHO case definition. We pooled data from the contributing studies, two large medical record databases in the United States, and findings from 44 published studies using a Bayesian meta-regression tool. We separately estimated occurrence and pattern of recovery in patients with milder acute infections and those hospitalized. We estimated the incidence and prevalence of long COVID globally and by country in 2020 and 2021 as well as the severity-weighted prevalence using disability weights from the Global Burden of Disease study. Results: Analyses are based on detailed information for 1906 community infections and 10526 hospitalized patients from the ten collaborating cohorts, three of which included children. We added published data on 37262 community infections and 9540 hospitalized patients as well as ICD-coded medical record data concerning 1.3 million infections. Globally, in 2020 and 2021, 144.7 million (95% uncertainty interval [UI] 54.8-312.9) people suffered from any of the three symptom clusters of long COVID. This corresponds to 3.69% (1.38-7.96) of all infections. The fatigue, respiratory, and cognitive clusters occurred in 51.0% (16.9-92.4), 60.4% (18.9-89.1), and 35.4% (9.4-75.1) of long COVID cases, respectively. Those with milder acute COVID-19 cases had a quicker estimated recovery (median duration 3.99 months [IQR 3.84-4.20]) than those admitted for the acute infection (median duration 8.84 months [IQR 8.10-9.78]). At twelve months, 15.1% (10.3-21.1) continued to experience long COVID symptoms. Conclusions and relevance: The occurrence of debilitating ongoing symptoms of COVID-19 is common. Knowing how many people are affected, and for how long, is important to plan for rehabilitative services and support to return to social activities, places of learning, and the workplace when symptoms start to wane.

Shaghayegh Haghjooy Javanmard | Christopher J. L. Murray | T. Vos | A. Ferrari | A. Aravkin | A. Flaxman | S. Hay | D. Pigott | B. Duncan | G. Bonsel | C. Abbafati | Z. Al-Aly | A. Carter | N. Fullman | J. Haagsma | Kristopher J. Krohn | R. Lozano | D. Malta | N. Mohammadifard | A. Mokdad | L. Monasta | R. Reiner | D. Santomauro | N. Sarrafzadegan | J. Soriano | C. Wiysonge | G. Ribbers | M. Puhan | J. Aerts | P. Glybochko | E. Castro | A. Gamkrelidze | J. Månsson | Farah Daoud | R. van den Berg-Emons | M. Kereselidze | Erin B Hamilton | M. Hellemons | A. Malinovschi | J. Peñalvo | Jiawei He | I. Larsson | E. Wallin | S. Rubertsson | R. Helbok | O. Ogbuoji | D. Buonsenso | H. Chu | P. Valentini | C. De Rose | R. Frithiof | D. McCulloch | B. Magistro | D. Menges | T. Ballouz | James Collins | Peng Zheng | C. Adolph | J. Albright | B. Bang-Jensen | Suman Chakrabarti | Xiaochen Dai | Samuel B. Ewald | E. Hulland | Alice Lazzar-Atwood | Akiaja Lindstrom | Maja Pašović | G. Reinke | A. Sholokhov | E. Spurlock | V. Rass | Nickolas Reinig | Chelsea Liu | D. Butnaru | A. Svistunov | Hanzhang Xu | M. Heijenbrok-Kal | J. Giles | M. Witzenrath | F. Kurth | W. Jassat | Nikita A. Nekliudov | M. M. Diab | B. J. van de Water | M. El Tantawi | W. Mao | M. Hultström | Charlie Ashbaugh | Kyle E Simpson | Sarah Wulf Hanson | J. Bettger | D. Munblit | A. Ricchiuto | D. Sinatti | A. M. Mantilla Herrera | M. Lipcsey | S. Huijts | C. Bisignano | Gaorui Guo | I. M. Osmanov | F. Steinbeis | Anastasia Shikhaleva | E. Samitova | Monika Helak | O. Blyuss | V. Fomin | M. S. Petersen | N. Nekliudov | G. Harris | R. Walcott | Callan Loflin | D. Hillus | Thomas Zoller | S. Borzakova | Austin Carter | C. Murray | Shuhei Nomura | P. Bobkova | Emil Ekbom | A. Gamirova | L. Mazankova | Mujibur Rahman | E. Spiridonova | Yifan Wu | Joanne O Amlag | Rachel Castellano | Carolyn Dapper | A. Deen | Megan Erickson | A. L. P. Ribeiro | Ally Walker | T. Zoller | Denise J. McCulloch | Kyle E. Simpson | Callan D Loflin | A. P. L. Ribeiro | Z. Al‐Aly | I. Osmanov | M. Diab | Gabrielle M. Harris | J. Collins | A. L. Ribeiro | X. Dai | Antonia Ricchiuto | Bree L Bang-Jensen | Beatrice Magistro | Grace Reinke | Verena Rass | Ewa Wallin | Emma Castro

[1]  Reed J. D. Sorensen,et al.  Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.

[2]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[3]  H. Bundgaard,et al.  Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study , 2022, The Lancet Child & Adolescent Health.

[4]  A. Slooter,et al.  Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19. , 2022, JAMA.

[5]  Shaghayegh Haghjooy Javanmard,et al.  Isfahan COVID cohort study: Rationale, methodology, and initial results , 2022, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[6]  I. Tleyjeh,et al.  Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up , 2021, PloS one.

[7]  Janet Diaz,et al.  A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[8]  Brendan R. Jackson,et al.  Long-Term Symptoms Among Adults Tested for SARS-CoV-2 — United States, January 2020–April 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[9]  A. Akbari,et al.  Long COVID in children and adolescents , 2021, World Journal of Pediatrics.

[10]  K. T. Kalleberg,et al.  Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study , 2021, PloS one.

[11]  G. Ribbers,et al.  CO-FLOW: COvid-19 Follow-up care paths and Long-term Outcomes Within the Dutch health care system: study protocol of a multicenter prospective cohort study following patients 2 years after hospital discharge , 2021, BMC Health Services Research.

[12]  L. Horwitz,et al.  Six-Month Outcomes in Patients Hospitalized with Severe COVID-19 , 2021, Journal of General Internal Medicine.

[13]  B. D. De Stavola,et al.  Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study) , 2021, BMJ Open.

[14]  N. Belfeki,et al.  Post-COVID-19 Syndrome: Nine Months after SARS-CoV-2 Infection in a Cohort of 354 Patients: Data from the First Wave of COVID-19 in Nord Franche-Comté Hospital, France , 2021, Microorganisms.

[15]  T. Spector,et al.  Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2 , 2021, The Lancet. Child & adolescent health.

[16]  A. Galiana,et al.  Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study , 2021, Journal of Clinical Immunology.

[17]  R. Guner,et al.  Post‐COVID syndrome: A single‐center questionnaire study on 1007 participants recovered from COVID‐19 , 2021, Journal of medical virology.

[18]  Post-Acute COVID Syndrome, the Aftermath of Mild to Severe COVID-19 in Brazilian Patients , 2021, medRxiv.

[19]  M. Isola,et al.  Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients , 2021, Clinical Microbiology and Infection.

[20]  R. Riera,et al.  Frequency, signs and symptoms, and criteria adopted for long COVID‐19: A systematic review , 2021, International journal of clinical practice.

[21]  Reed J. D. Sorensen,et al.  Trends in Patient Characteristics and COVID-19 In-Hospital Mortality in the United States During the COVID-19 Pandemic , 2021, JAMA network open.

[22]  D. Stuart,et al.  The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom , 2021, medRxiv.

[23]  A. Steer,et al.  Post-acute COVID-19 outcomes in children with mild and asymptomatic disease , 2021, The Lancet Child & Adolescent Health.

[24]  M. A.,et al.  Impaired diffusing capacity for carbon monoxide is common in critically ill Covid-19 patients at four months post-discharge , 2021, Respiratory Medicine.

[25]  Md. Mujibur Rahman,et al.  Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh , 2021, PloS one.

[26]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[27]  W. Lim,et al.  Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol , 2021, The Lancet Regional Health - Europe.

[28]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[29]  A. Azman,et al.  Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance , 2021, medRxiv.

[30]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[31]  12,et al.  SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay , 2021, medRxiv.

[32]  Milad Asgari Mehrabadi,et al.  COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic , 2021, medRxiv.

[33]  J. Barberà,et al.  Lung Function Sequelae In Covid-19 Patients 3 Months After Hospital Discharge , 2021, Archivos de Bronconeumología.

[34]  Y. Benjamini,et al.  Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients , 2021, Clinical Microbiology and Infection.

[35]  F. Anastasio,et al.  Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life , 2021, European Respiratory Journal.

[36]  C. Wolf,et al.  Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.

[37]  D. Buonsenso,et al.  Preliminary evidence on long COVID in children , 2021, medRxiv.

[38]  A. Larsson,et al.  Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19 , 2021, Critical Care.

[39]  Benjamin Bowe,et al.  High-dimensional characterization of post-acute sequelae of COVID-19 , 2021, Nature.

[40]  S. Villapol,et al.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[41]  A. Bellasi,et al.  Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation , 2021, Epidemiology and Infection.

[42]  M. Andrés,et al.  Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study , 2021, Journal of Infection.

[43]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[44]  E. Price-Haywood,et al.  The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study , 2021, Clinical Microbiology and Infection.

[45]  C. Gramaglia,et al.  Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge , 2021, JAMA network open.

[46]  S. Kiechl,et al.  Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study , 2020, European journal of neurology.

[47]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[48]  Patients With Uncomplicated Coronavirus Disease 2019 (COVID-19) Have Long-Term Persistent Symptoms and Functional Impairment Similar to Patients with Severe COVID-19: A Cautionary Tale During a Global Pandemic , 2021 .

[49]  N. Wig,et al.  Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. , 2021, Drug discoveries & therapeutics.

[50]  A. Komaroff,et al.  Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? , 2021, Frontiers in Medicine.

[51]  M. Sivan,et al.  NICE guideline on long covid , 2020, BMJ.

[52]  K. Stavem,et al.  Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19 , 2020, European Respiratory Journal.

[53]  C. Ryerson,et al.  A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations , 2020, Thorax.

[54]  N. Lorenzo-Villalba,et al.  Ninety days post-hospitalization evaluation of residual COVID-19 symptoms through a phone call check list , 2020, The Pan African medical journal.

[55]  P. Weihe,et al.  Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  V. F. Simões,et al.  Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão , 2020, Revista de saude publica.

[57]  S. Madhi,et al.  Long-COVID: An evolving problem with an extensive impact. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[58]  J. Ludvigsson Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19 , 2020, Acta paediatrica.

[59]  T. Greenhalgh,et al.  Developing services for long Covid: lessons from a study of wounded healers , 2020, medRxiv.

[60]  V. Chopra,et al.  Sixty-Day Outcomes Among Patients Hospitalized With COVID-19 , 2020, Annals of Internal Medicine.

[61]  P. Bieniasz,et al.  Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients , 2020, The Journal of Infectious Diseases.

[62]  Jeremy S. Brown,et al.  ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19 , 2020, Thorax.

[63]  E. Bonifacio,et al.  A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children , 2020, Med.

[64]  H. Krumholz,et al.  Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study , 2020, The American Journal of Medicine.

[65]  C. Donnelly,et al.  Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults , 2020, medRxiv.

[66]  N. Washington,et al.  Long-term COVID-19 symptoms in a large unselected population , 2020 .

[67]  F. Callard,et al.  How and why patients made Long Covid , 2020, Social Science & Medicine.

[68]  F. Bruyère,et al.  Follow-up of adults with noncritical COVID-19 two months after symptom onset , 2020, Clinical Microbiology and Infection.

[69]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[70]  B. Fantin,et al.  Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 , 2020, Journal of Infection.

[71]  N. Maskell,et al.  Patient outcomes after hospitalisation with COVID-19 and implications for follow-up; results from a prospective UK cohort. , 2020, medRxiv.

[72]  Manoj Sivan,et al.  Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation , 2020, Journal of medical virology.

[73]  P. Kirchhof,et al.  Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. , 2020, JAMA cardiology.

[74]  M. Devita,et al.  Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19. , 2020, Journal of the American Society of Nephrology : JASN.

[75]  K. Jhaveri,et al.  COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. , 2020, Journal of the American Society of Nephrology : JASN.

[76]  M. Hernán,et al.  Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.

[77]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[78]  C. von Kalle,et al.  Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19) , 2020, Infection.

[79]  J. Kuhle,et al.  Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 , 2020, Journal of Neurology.

[80]  Eric J Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[81]  A. Abdullahi,et al.  Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19 , 2020, Physiotherapy theory and practice.

[82]  F. Tacke,et al.  Studying the pathophysiology of coronavirus disease 2019 - a protocol for the Berlin prospective COVID-19 patient cohort (Pa- COVID-19) , 2020, medRxiv.

[83]  W. Brady,et al.  Cardiovascular complications in COVID-19 , 2020, The American Journal of Emergency Medicine.

[84]  John S. Brownstein,et al.  Epidemiological data from the COVID-19 outbreak, real-time case information , 2020, Scientific Data.

[85]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[86]  Peng Zheng,et al.  Trimmed Constrained Mixed Effects Models: Formulations and Algorithms , 2019, bioRxiv.

[87]  A. Komaroff Advances in Understanding the Pathophysiology of Chronic Fatigue Syndrome. , 2019, JAMA.

[88]  T. Vos,et al.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.

[89]  Emmanouel A. Varvarigos,et al.  Survey , 2016, ACM Comput. Surv..

[90]  Mirjam Kretzschmar,et al.  Disability weights for the Global Burden of Disease 2013 study. , 2015, The Lancet. Global health.

[91]  D. Needham,et al.  Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference* , 2012, Critical care medicine.

[92]  H. Moldofsky,et al.  Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study , 2011, BMC neurology.

[93]  Bernice B Brown,et al.  DELPHI PROCESS: A METHODOLOGY USED FOR THE ELICITATION OF OPINIONS OF EXPERTS , 1968 .